What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1][2]. Company Overview: Xeris Biopharma (XERS) - Xeris Biopharma currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating strong potential for performance [3][4]. - The stock has shown a price increase of 0.26% over the past week, outperforming the flat performance of the Zacks Medical - Drugs industry [6]. - Over the past month, XERS has risen by 7.92%, compared to the industry's 2.14% [6]. - In the last three months, XERS shares have increased by 76.59%, and by 191.01% over the past year, significantly outperforming the S&P 500's gains of 8.64% and 21.49%, respectively [7]. Trading Volume - XERS has an average 20-day trading volume of 2,082,965 shares, which is a useful indicator of market interest and price movement [8]. Earnings Outlook - In the past two months, three earnings estimates for XERS have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from -$0.07 to -$0.03 [10]. - For the next fiscal year, three estimates have also moved upwards, indicating positive sentiment [10]. Conclusion - Given the positive price trends and earnings outlook, Xeris Biopharma is positioned as a strong momentum pick, meriting attention from investors [12].